New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar
On this episode of Not So Different, we spoke with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, to discuss the US launch of Byooviz, the first ophthalmology biosimilar in the United States, and how it's expected to impact ophthalmology care.
On this episode of Not So Different, we spoke with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, to discuss the US launch of Byooviz, the first ophthalmology biosimilar and the first biosimilar referencing Lucentis (ranbizumab) in the United States. We also talked about how this launch is expected to impact ophthalmology care going forward and what needs to be done to ensure patients have adequate access to this biosimilar and other ophthalmology biosimilars in the future.
Show Notes:
To learn more about the US launch of Byooviz, click here.
To read more about the anticipation for ophthalmology biosimilars, click here.
To read more of Dr. Oskouei’s comments on “Round 2,” click here.
To learn more about the EU approval of Byooviz, click here.
To learn more about the Canadian approval of Byooviz, click here.
To read more on the anticipation for aflibercept biosimilars, click here.
